Official registry condition

Neuroendocrine Tumors peptide trials

8 selected ClinicalTrials.gov records carrying the official condition label Neuroendocrine Tumors. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

8 selected records.

Connected peptides

4 profiles.

Registry update years

2018–2026 in selected records.

Indication intelligence

Selected evidence landscape

Trial phases4

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses2

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 110 selected PubMed records and 32 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Neuroendocrine Tumors unless their own cited source says so.

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT03206060

PeptideScanner retained ClinicalTrials.gov record NCT03206060 at 2026-11-16T17:36:42.191Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
October 26, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03590119

PeptideScanner retained ClinicalTrials.gov record NCT03590119 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-11-08, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
November 8, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04954820

PeptideScanner retained ClinicalTrials.gov record NCT04954820 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
June 4, 2026
Evidence lane
Clinical trials

Attributed registry records

Selected records

All trial facets →